Phase 2 N=9 PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Primary: Electrocardiograms (ECG) — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent High Grade B-Cell Lymphoma · Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I) — 0; 1; 2; 0 Participants
Phase 2 N=625 Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
Lyme Borreliosis
Primary: Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1 — 63.0; 59.3; 12.5; 60.4 Percentage of…
Phase 2 N=230 An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB) — 30; 50; 58.8; 30.3 Percent of Participants
Phase 2 N=25 High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
Soft Tissue Sarcoma
Primary: Number of Participants That Experienced Dose Limiting Toxicities (DLTs) Using CTCAE, Version 4.0 — 0 participants
Phase 2 N=11 A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
Parkinson Disease · Cognitive Dysfunction
Primary: Part A: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 45.5 percentage of participants
Phase 2 N=71 LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in Chronic Sinusitis Symptom Scores at Week 4 — -2.24; -2.65; -2.28 score on a scale
Phase 2 N=149 Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain
Lumbosacral Radiculopathy
Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale…
Phase 2 N=200 A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination — 4.0; 29.3; 4.0; 43.3 percentage of participants
Phase 2 N=56 Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
Anemia · Myelodysplastic/Myeloproliferative Neoplasm · Myelofibrosis
Primary: Anemia-response — 8; 6 Participants
Phase 2 N=50 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · Primary Myelofibrosis · Secondary Myelofibrosis
Primary: Number of Participants With a Response — 15 Participants
Phase 2 N=108 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Peripheral T Cell Lymphoma · Transformed Mycosis Fungoides
Primary: Overall Response Rate Assessed by Independent Review Committee Based on PET-CT — 32.4 percentage — p=0.051
Phase 2 N=11 Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Fatigue · Quality of Life
Primary: Fatigue Severity Scale (FSS) — 4; 2 Participants
Phase 2 N=37 Stellate Ganglion Block (SGB) For Women for Breast Cancer
Hot Flushes · Hot Flashes
Primary: Change in Number of Night Sweats From Baseline to 6 Months After Intervention. — 5.46; 10.09 night sweats/month
Phase 2 N=820 Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study
Chronic Pain
Primary: Pain Response — 58; 54 Participants